Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khalid Zoghebi

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Current Medicinal Chemistry|May 21, 2026
Structure-Based Identification of Natural Product-Derived BCL-2 Inhibitors as Potential Therapeutics for Hepatocellular CarcinomaKhalid Zoghebi, Asim Najmi
Current Pharmaceutical Design|September 8, 2025
Flavonoids as Dual Inhibitors of MELK and LYN Kinases in Cervical Cancer: An In Silico Molecular Docking AnalysisKhalid Zoghebi, Abdulmajeed M Jali
Biomolecules|June 27, 2024
Insights into the Effects of Ligand Binding on Leucyl-tRNA Synthetase Inhibitors for Tuberculosis: In Silico Analysis and Isothermal Titration Calorimetry ValidationZia Ur Rehman, Asim Najmi, Khalid Zoghebi
Journal of Biomolecular Structure & Dynamics|December 11, 2024
Exploring the anti-cancer properties of <i>Carissa carandas</i> as a multi-targeted approach against breast cancerKhalid Zoghebi, Fahad Y Sabei, Awaji Y Safhi
Current Drug Targets|February 11, 2026
Tachykinin Receptors and their Antagonists: Unraveling Their Role in Metabolic Disorders and Therapeutic InnovationsWaquar Ahsan, Sadique A Javed, Asim Najmi, et al.
Cells|January 21, 2022
[(WR)<sub>8</sub>WKβA]-Doxorubicin Conjugate: A Delivery System to Overcome Multi-Drug Resistance against DoxorubicinKhalid Zoghebi, Hamidreza Montazeri Aliabadi, Rakesh Kumar Tiwari, et al.
Frontiers in Immunology|April 25, 2024
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challengesSadique A Javed, Asim Najmi, Waquar Ahsan, et al.
Molecular Pharmaceutics|September 7, 2021
Hybrid Cyclic-Linear Cell-Penetrating Peptides Containing Alternative Positively Charged and Hydrophobic Residues as Molecular TransportersSorour Khayyatnejad Shoushtari, Khalid Zoghebi, Muhammad Imran Sajid, et al.
Molecular Pharmaceutics|November 29, 2022
Cyclic and Linear Peptides Containing Alternate WW and RR Residues as Molecular Cargo Delivery ToolsLois Kim, Sandeep Lohan, Jonathan Moreno, et al.
Cells|April 12, 2022
Amphiphilic Cell-Penetrating Peptides Containing Natural and Unnatural Amino Acids as Drug Delivery AgentsDavid Salehi, Saghar Mozaffari, Khalid Zoghebi, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Current Medicinal Chemistry|May 21, 2026
Structure-Based Identification of Natural Product-Derived BCL-2 Inhibitors as Potential Therapeutics for Hepatocellular CarcinomaKhalid Zoghebi, Asim Najmi
Current Pharmaceutical Design|September 8, 2025
Flavonoids as Dual Inhibitors of MELK and LYN Kinases in Cervical Cancer: An In Silico Molecular Docking AnalysisKhalid Zoghebi, Abdulmajeed M Jali
Biomolecules|June 27, 2024
Insights into the Effects of Ligand Binding on Leucyl-tRNA Synthetase Inhibitors for Tuberculosis: In Silico Analysis and Isothermal Titration Calorimetry ValidationZia Ur Rehman, Asim Najmi, Khalid Zoghebi
Journal of Biomolecular Structure & Dynamics|December 11, 2024
Exploring the anti-cancer properties of <i>Carissa carandas</i> as a multi-targeted approach against breast cancerKhalid Zoghebi, Fahad Y Sabei, Awaji Y Safhi
Current Drug Targets|February 11, 2026
Tachykinin Receptors and their Antagonists: Unraveling Their Role in Metabolic Disorders and Therapeutic InnovationsWaquar Ahsan, Sadique A Javed, Asim Najmi, et al.
Cells|January 21, 2022
[(WR)<sub>8</sub>WKβA]-Doxorubicin Conjugate: A Delivery System to Overcome Multi-Drug Resistance against DoxorubicinKhalid Zoghebi, Hamidreza Montazeri Aliabadi, Rakesh Kumar Tiwari, et al.
Frontiers in Immunology|April 25, 2024
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challengesSadique A Javed, Asim Najmi, Waquar Ahsan, et al.
Molecular Pharmaceutics|September 7, 2021
Hybrid Cyclic-Linear Cell-Penetrating Peptides Containing Alternative Positively Charged and Hydrophobic Residues as Molecular TransportersSorour Khayyatnejad Shoushtari, Khalid Zoghebi, Muhammad Imran Sajid, et al.
Molecular Pharmaceutics|November 29, 2022
Cyclic and Linear Peptides Containing Alternate WW and RR Residues as Molecular Cargo Delivery ToolsLois Kim, Sandeep Lohan, Jonathan Moreno, et al.
Cells|April 12, 2022
Amphiphilic Cell-Penetrating Peptides Containing Natural and Unnatural Amino Acids as Drug Delivery AgentsDavid Salehi, Saghar Mozaffari, Khalid Zoghebi, et al.
Pageof 4